October 29, 2020 at 9:00 AM EDT Download PDF VANCOUVER, British Columbia & PALO ALTO, Calif.–(BUSINESS WIRE)–AbCellera and Kodiak Sciences Inc. (Nasdaq: KOD), today announced a new partnership to generate therapeutic antibody candidates in ophthalmology. Following a previously successful collaboration, AbCellera will use its full stack, AI-powered antibody discovery technology to discover and identify a large … Continued

VISTA CENTER and KODIAK SCIENCES UNITE TO RAISE AWARENESS AND EXPAND SUPPORT FOR PEOPLE LIVING WITH VISION LOSS Palo Alto, CA – June 1, 2020 – Vista Center for the Blind and Visually Impaired, a nonprofit serving individuals living with vision loss, today announced its partnership with Kodiak Sciences to launch the Live Your Best Life campaign. Kodiak is a clinical … Continued

PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2020. “We have made strong progress across the entire company this quarter— clinical, manufacturing, research and corporate. … Continued

– Strong anti-VEGF safety, efficacy and durability continue to be observed across all three of the major retinal vascular diseases, with most patients achieving treatment-free intervals of 6-months in wet AMD, 6-months or longer in DME, and 4-months or longer in RVO – 82% of wet AMD eyes extended to 4-months or longer before first … Continued

PALO ALTO, Calif., July 7, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming American Society of Retina Specialists (ASRS) 2020 Virtual … Continued

PALO ALTO, Calif., May 28, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming virtual investor conferences: Jefferies Virtual Healthcare Conference on Thursday, June 4 at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time) Goldman Sachs 41st Annual Global Healthcare … Continued

PALO ALTO, Calif., May 11, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2020. “I am proud of the dedication and passion of our people who continue to deliver on our … Continued

PALO ALTO, Calif., May 8, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a business highlights webcast on Tuesday, May 12, 2020 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live webcast of the presentation will be available on the “Events … Continued

PALO ALTO, Calif., April 2, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors. Charlie recently retired from a successful career at Bristol Myers Squibb (BMS) where he held a number of leadership roles in commercial, … Continued

PALO ALTO, Calif., March 24, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that the company received full registration of their trademarks “Kodiak” and “Kodiak Sciences” from the U.S. Patent and Trademark Office for the exclusive use of Kodiak Sciences Inc. and its subsidiaries. “Obtaining exclusive … Continued